Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

NCT01832857 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cornerstone Pharmaceuticals